InMode (INMD) Stock Price, News & Analysis

Company Overview

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Key Stats

• Today's Range: $14.24 to $14.78
• 50-Day Range: $14.10 to $18.30
• 52-Week Range: $13.68 to $19.85
• Volume: 1.17 million shs
• Average Volume: 1.19 million shs
• Market Capitalization: $928.54 million
• P/E Ratio: 6.25
• Dividend Yield: N/A
• Price Target: $18.54
• Consensus Rating: Hold

InMode Stock Analysis - MarketRank™

InMode scored higher than 77% of companies evaluated by MarketBeat, and ranked 237th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

InMode has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

InMode has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.00%

Earnings Growth

Earnings for InMode are expected to grow by 4.00% in the coming year, from $1.75 to $1.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InMode is 6.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of InMode is 6.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.

Price to Book Value per Share Ratio

InMode has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.00% of the float of InMode has been sold short.

Short Interest Ratio / Days to Cover

InMode has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in InMode has recently decreased by 11.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InMode does not currently pay a dividend.

Dividend Growth

InMode does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.00% of the float of InMode has been sold short.

Short Interest Ratio / Days to Cover

InMode has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in InMode has recently decreased by 11.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.20

News Sentiment

InMode has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for InMode this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for INMD on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

2 people have added InMode to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InMode insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.92% of the stock of InMode is held by insiders.

Percentage Held by Institutions

68.04% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INMD Stock Analysis - Frequently Asked Questions

How have INMD shares performed this year?

InMode's stock was trading at $16.70 at the start of the year. Since then, INMD shares have decreased by 12.0% and is now trading at $14.69.
View the best growth stocks for 2025 here.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) posted its earnings results on Monday, April, 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.45 by $0.14. The firm's revenue for the quarter was down 3.0% on a year-over-year basis.
Read the conference call transcript.

When did InMode's stock split?

InMode's stock split on the morning of Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly minted shares were payable to shareholders after the closing bell on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does InMode have any subsidiaries?

InMode subsidiaries include Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..

When did InMode IPO?

InMode (INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

Who are InMode's major shareholders?

InMode's top institutional shareholders include LSV Asset Management (2.89%), Boston Trust Walden Corp (1.96%), Goldman Sachs Group Inc. (1.62%) and Systematic Financial Management LP (1.51%).

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InMode investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Voya Infrastructure, Industrials and Materials Fund (IDE), Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 4/28/2025
• Today: 5/31/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INMD
• CIK: 1742692
• Web: www.inmodemd.com
• Phone: 972-4909-7470
• Fax: N/A
• Employees: 480
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $18.54
• High Stock Price Target: $25.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +26.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.33
• Trailing P/E Ratio: 6.25
• Forward P/E Ratio: 8.39
• P/E Growth: N/A
• Net Income: $181.27 million
• Net Margins: 45.91%
• Pretax Margin: 36.34%
• Return on Equity: 18.25%
• Return on Assets: 16.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.23
• Quick Ratio: 9.38

Sales & Book Value

• Annual Sales: $392.41 million
• Price / Sales: 2.37
• Cash Flow: $1.41 per share
• Price / Cash Flow: 10.40
• Book Value: $10.12 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 63,209,000
• Free Float: 64,746,000
• Market Cap: $928.54 million
• Optionable: Optionable
• Beta: 2.02